We are live on ! Find out more
AICPI

ABG Innovation Capital Partners III Portfolio holdings

AUM $64.5K
1-Year Est. Return 1.01%
This Fund
S&P 500
This Quarter Est. Return
+50.09%
1 Year Est. Return
+1.01%
3 Year Est. Return
+5.56%
5 Year Est. Return
-85.52%
10 Year Est. Return
–
AUM
$170M
AUM Growth
–
Cap. Flow
+$128M
Cap. Flow %
75.44%
Top 10 Hldgs %
100%
Holding
7
New
7
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$85.1M
2
LUNG icon
Pulmonx
LUNG
+$40.8M
3
GNCA
Genocea Biosciences, Inc.
GNCA
+$854K
4
WHWK
Whitehawk Therapeutics
WHWK
+$570K
5
SYBX
Synlogic
SYBX
+$438K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVIR icon
1
Atea Pharmaceuticals
AVIR
$382M
$110M 64.92%
+2,639,178
New +$85.1M
LUNG icon
2
Pulmonx
LUNG
$84.5M
$57.5M 33.86%
+833,333
New +$40.8M
GNCA
3
DELISTED
Genocea Biosciences, Inc.
GNCA
$908K 0.53%
+375,000
New +$854K
SYBX
4
DELISTED
Synlogic
SYBX
$445K 0.26%
+13,727
New +$438K
WHWK
5
Whitehawk Therapeutics
WHWK
$205M
$392K 0.23%
+26,667
New +$570K
ACGN
6
DELISTED
Aceragen Inc
ACGN
$206K 0.12%
+3,312
New +$190K
NBRV
7
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$111K 0.07%
+1,834
New +$199K

Similar funds

FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
SNN
Shen Neil Nanpeng $36.3K AUM 179.45% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
MI
Motiv8 Investments Port St. Lucie, Florida $183K AUM 15.06% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
NA
Newport Asia San Francisco, California $2.21M AUM
IVSFI
IA Venture Strategies Fund II New York $4.08M AUM 174.71% 1-Year Est. Return

ABG Innovation Capital Partners III's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for ABG Innovation Capital Partners III, which disclosed 7 positions worth $170M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Atea Pharmaceuticals: 2,639,178 shares worth $110M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • ABG Innovation Capital Partners III's largest Q4 2020 buy was Atea Pharmaceuticals: 2,639,178 shares worth $110M.
  • ABG Innovation Capital Partners III's ten largest holdings make up 100% of its $170M portfolio in Q4 2020.
  • ABG Innovation Capital Partners III disclosed 7 positions in Q4 2020, its first 13F filing on record.

Based on ABG Innovation Capital Partners III's 13F filing for Q4 2020, filed 16 Feb 2021.